Lexicon Pharmaceuticals | LXRX - Passività Correnti





Passività Correnti Cambiamento Data
Abbott USD 16.5B 1.91B 2025-12
Acadia Pharmaceuticals USD 277.11M 79.47M 2025-12
Agios Pharmaceuticals USD 82.21M 7.45M 2025-12
Akebia Therapeutics USD 162.94M 29.56M 2025-12
Alnylam Pharmaceuticals USD 1.47B 89.13M 2025-12
AstraZeneca USD 30.62B 3.44B 2025-12
BioMarin Pharmaceutical USD 759.03M 39.41M 2025-12
Coherus Biosciences USD 140.39M 231.91M 2025-12
Eli Lilly USD 35.23B 4.91B 2025-12
Esperion Therapeutics USD 300.81M 58.22M 2025-12
Halozyme Therapeutics USD 177.09M 660.14M 2025-12
Illumina USD 1.59B 377M 2025-12
Insmed USD 468.87M 51.66M 2025-12
Ironwood Pharmaceuticals USD 242.5M 9.98M 2025-09
J&J USD 54.13B 3.26B 2025-12
Lexicon Pharmaceuticals USD 20.87M 853K 2025-12
MacroGenics USD 43.11M 1.36M 2025-12
MannKind USD 171.03M 61.9M 2025-12
Merck USD 28.63B 2.59B 2025-09
Moderna USD 1.99B 306M 2025-12
Novartis USD 27.28B 4.72B 2025-12
PTC Therapeutics USD 968.43M 102.18M 2025-12
Puma Biotechnology USD 82.73M 3.63M 2025-09
Sarepta Therapeutics USD 1.1B 173.86M 2025-12
Thermo Fisher Scientific USD 15.19B 301M 2025-12
Ultragenyx Pharmaceutical USD 340.02M 46.78M 2025-09
United Therapeutics USD 560.6M 14.3M 2025-12
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12